GEN-MKT-18-7897-A
Aug 1, 2019 | Blogs, Forensic | 0 comments
Elevate Performance in Your Forensic Toxicology LabYou only need to skim through the United Nations World Drug Report 2018 to see that drug abuse is escalating. Associated with numerous medical, social, and legal problems, it comes as no surprise that ‘drugs of abuse’ testing is an increasingly important task in forensic toxicology. Identifying drugs in biological samples provides scientific evidence in court. With this in mind, the forecasted 9.6% CAGR in the global drug of abuse testing market during 2017-2023 is not only inevitable, but further reinforces the crisis.
If you work in a forensic toxicology lab, you don’t need to read these statistics to know that the pressure is on. New designer drugs are emerging on the market on a monthly basis and the number of case samples to process keeps ramping up. This presents a new challenge as forensic toxicology laboratories are experiencing severe backlogs, putting a burden on the ability to quickly screen new samples. What you need is a sensitive and comprehensive analytical system for comprehensive screening of biological samples, so you can quickly complete your case investigation after receiving a sample.
Enhance Performance with Powerful, Highly Sensitive InstrumentsAs a first-line screening method, immunoassays are most commonly used to detect abused drugs in biological samples. Although it is a fast, convenient and relatively inexpensive method for basic screening, its potential remains limited due to insufficient specificity and coverage. Gas chromatography-mass spectrometry (GC-MS) has long been the technique of choice for illicit drug analysis in forensic toxicology. While GC-MS offers high sensitivity and good separation power, it requires extensive sample preparation with sample derivatization and lengthy analysis methods. This introduces long run times and results in a mounting case backlog.
In recent years, we have seen GC-MS become overshadowed by the rapid turnaround time, ease of use and high sensitivity of an alternative technique. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) with multiple reaction monitoring (MRM) offers significant performance benefits to forensic investigators. It has become the method of choice for quantitative analysis of abused drugs because it offers several advantages over GC-MS, such as faster sample extraction and simultaneous analysis of a broader range of compounds.
Sounds Great, But Can We Prove It?We certainly can, and we invite you to read the technical paper entitled Elevating the Forensic Laboratory Performance – Application of the SCIEX Triple Quad™ 3500 LM-MS/MS System for Rapid Analysis of Drugs of Abuse in our recently published Forensics Compendium.
You will see how we have developed a method for rapid, reliable and comprehensive analysis of forensic drugs in urine samples. You will see how the use of a polarity switching method due to the inclusion of several barbiturates, and an optimized Scheduled MRM™ algorithm allows detection of over 200 forensic compounds. You will also see how a runtime of approximately 6.5 minutes was achieved to accommodate detection of all the drugs of abuse in the same, and how the runtime can be reduced to 5 minutes with a smaller targeted list (<60 analytes).
The results highlight much faster sample analysis when compared to a 15-17 minute GS-MS workflow. With the ability to process more than 285 samples within a 24-hour timeframe using a 5 minute LC run time, you can see why the forensic laboratory is quickly turning to LC-MS/MS to significantly increase turnaround time and reduce large case backlogs.
With the prospect of more efficient workflows and shorter run times, download the Forensics Compendium to read the tech note today and find out how your lab can improve performance with a fully-developed and proven LC-MS/MS method.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network